BioSpace News Archive

TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.

resTORbio, Inc. announced that management will present at two upcoming investor conferences

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET.

BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session

The government said Petit and former Chief Operating Officer William Taylor engaged in a scheme to “fraudulently inflate” the revenue of MiMedx.

Researchers found that the treatment delayed the development of ALS symptoms in the mice with the ALS mutations.

Companies from across the globe provide updates on their businesses and pipelines.

While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.

Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.

MaxiVAX wins grant among 94 projects funded out of 2,015 applications